Cerebral

Online mental health services subscription provider

San Francisco, California, United States

About Cerebral

Cerebral provides online mental health services aimed at individuals seeking support. The company operates through a subscription model, allowing customers to pay a monthly fee for access to various mental health resources. Users can be matched with licensed therapists or prescribers, receive ongoing support, and schedule sessions through a user-friendly app. Additionally, Cerebral offers a medication plan, delivering prescribed medications directly to customers or to a pharmacy of their choice. What sets Cerebral apart from competitors is its comprehensive approach that combines therapy and medication, which has been shown to significantly reduce the chances of major depression recurrence. The goal of Cerebral is to make mental health care accessible and affordable, providing personalized support to those in need.

San Francisco, CaliforniaHeadquarters
2020Year Founded
$449.4MTotal Funding
SERIES_CCompany Stage
HealthcareIndustries
501-1,000Employees

Benefits

Remote-first
Medical, dental, vision, & life insurance
401k
Unlimited PTO
Wellness stipend
Bi-quarterly mental health days
No-Meeting-Wednesdays
Social events
Optional company retreats

Risks

Increased competition from companies like BetterHelp and Talkspace.
Concerns over data privacy and security in telehealth services.
Regulatory scrutiny over online medication prescriptions.

Differentiation

Cerebral offers a comprehensive subscription model combining therapy and medication.
The company provides flexible, online mental health services accessible to a broad market.
Cerebral employs licensed therapists and prescribers for personalized mental health care.

Upsides

Cerebral raised $300M in Series C funding, boosting its growth potential.
The mental health app market is projected to grow significantly, benefiting Cerebral.
Increased demand for telemedicine due to COVID-19 expands Cerebral's user base.

Funding

Total raised$449.40 M
Latest valuation$4.80 B
StageSERIES_C